Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Werewolf Therapeutics (HOWL) Share-based Compensation (2021 - 2025)

Werewolf Therapeutics (HOWL) has disclosed Share-based Compensation for 5 consecutive years, with $1.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Share-based Compensation fell 38.69% to $1.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $6.9 million, a 21.06% decrease, with the full-year FY2024 number at $8.8 million, up 10.21% from a year prior.
  • Share-based Compensation was $1.2 million for Q3 2025 at Werewolf Therapeutics, down from $1.8 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $2.6 million in Q2 2024 to a low of $539000.0 in Q1 2021.
  • A 5-year average of $1.8 million and a median of $1.9 million in 2024 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: surged 223.75% in 2022, then tumbled 38.69% in 2025.
  • Werewolf Therapeutics' Share-based Compensation stood at $1.3 million in 2021, then soared by 49.85% to $1.9 million in 2022, then dropped by 3.55% to $1.9 million in 2023, then increased by 1.87% to $1.9 million in 2024, then tumbled by 35.38% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for HOWL's Share-based Compensation are $1.2 million (Q3 2025), $1.8 million (Q2 2025), and $2.0 million (Q1 2025).